How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?

Should these patients have a different threshold for utilizing a CDK4/6 inhibitor in the front line metastatic or as part of adjuvant therapy, or SERDs where eligible?

Answer from: Medical Oncologist at Community Practice

In patients with germline mutations such as BRCA1/2, we have learned that the use of CDK4/6 inhibitors may have less of an impact, suggesting some degree of inherent endocrine therapy resistance. In one retrospective analysis of patients with germline mutations in homologous recombination repair (su...

Comments

Medical Oncologist at NYU Winthrop Hospital
Great review

Medical Oncologist at NorthEast Onc Assocs
Great summary and guidance in this patient populat...

Please select the option that best describes you:

How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?

Related Questions